Korean J Gastroenterol.  2021 Aug;78(2):105-116. 10.4166/kjg.2021.112.

KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement

Affiliations
  • 1Division of Gastroenterology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
  • 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
  • 3Department of Health Promotion Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea
  • 4Division of Gastroenterology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea
  • 5Digestive Disease Center, CHA Bundang Hospital, CHA University, Seongnam, Korea
  • 6Division of Gastroenterology, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea
  • 7Center for Colorectal Cancer, National Cancer Center, Goyang, Korea
  • 8Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine , Hwaseong, Korea
  • 9Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea
  • 10Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency , Seoul, Korea
  • 11Division of Gastroenterology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine , Seoul, Korea
  • 12Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Korea

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.

Keyword

SARS-CoV-2; COVID-19; Inflammatory bowel diseases; Disease management

Cited by  1 articles

Epidemiological Trends of Pediatric Inflammatory Bowel Disease in Korea: A Multicenter Study of the Last 3 Years Including the COVID-19 Era
So Yoon Choi, Sujin Choi, Ben Kang, Byung-Ho Choe, Yeoun Joo Lee, Jae Hong Park, Yu Bin Kim, Jae Young Kim, Kunsong Lee, Kyung Jae Lee, Ki Soo Kang, Yoo Min Lee, Hyun Jin Kim, Yunkoo Kang, Hyo-Jeong Jang, Dae Yong Yi, Suk Jin Hong, You Jin Choi, Jeana Hong, Soon Chul Kim
J Korean Med Sci. 2022;37(37):e279.    doi: 10.3346/jkms.2022.37.e279.


Reference

1. Perlman S. 2020; Another decade, another coronavirus. N Engl J Med. 382:760–762. DOI: 10.1056/NEJMe2001126. PMID: 31978944. PMCID: PMC7121143.
Article
2. Sohrabi C, Alsafi Z, O'Neill N, et al. 2020; World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 76:71–76. DOI: 10.1016/j.ijsu.2020.02.034. PMID: 32112977. PMCID: PMC7105032.
Article
3. Bezzio C, Saibeni S, Variola A, et al. 2020; Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 69:1213–1217. DOI: 10.1136/gutjnl-2020-321411. PMID: 32354990. PMCID: PMC7242872.
Article
4. Chen N, Zhou M, Dong X, et al. 2020; Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 395:507–513. DOI: 10.1016/S0140-6736(20)30211-7. PMID: 32007143. PMCID: PMC7135076.
Article
5. Choi CH, Moon W, Kim YS, et al. 2017; Second Korean Guideline for the management of ulcerative colitis. Korean J Gastroenterol. 69:1–28. DOI: 10.4166/kjg.2017.69.1.1. PMID: 28135789.
Article
6. Park JJ, Yang SK, Ye BD, et al. 2017; Second Korean Guidelines for the management of Crohn's disease. Korean J Gastroenterol. 69:29–54. DOI: 10.4166/kjg.2017.69.1.29. PMID: 28135790.
Article
7. Kim JM, Cheon JH. 2020; Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases. Intest Res. 18:249–264. DOI: 10.5217/ir.2019.00128. PMID: 32295331. PMCID: PMC7385581.
Article
8. Winthrop KL, Melmed GY, Vermeire S, et al. 2018; Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 24:2258–2265. DOI: 10.1093/ibd/izy131. PMID: 29850873. PMCID: PMC6140434.
Article
9. Pauly MP, Tucker LY, Szpakowski JL, et al. 2018; Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 16:1964–1973.e1. DOI: 10.1016/j.cgh.2018.04.033. PMID: 29702293.
Article
10. Ooi CJ, Hilmi I, Banerjee R, et al. 2019; Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol. 34:1296–1315. DOI: 10.1111/jgh.14648. PMID: 30848854.
Article
11. Attauabi M, Poulsen A, Theede K, et al. 2021; Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease-a Danish prospective population-based cohort study. J Crohns Colitis. 15:540–550. DOI: 10.1093/ecco-jcc/jjaa205. PMID: 33035299. PMCID: PMC7797764.
Article
12. Derikx LAAP, Lantinga MA, de Jong DJ, et al. 2021; Clinical outcomes of COVID-19 in patients with inflammatory bowel disease: a nationwide cohort study. J Crohns Colitis. 15:529–539. DOI: 10.1093/ecco-jcc/jjaa215. PMID: 33079178. PMCID: PMC7665430.
Article
13. Aziz M, Fatima R, Haghbin H, Lee-Smith W, Nawras A. 2020; The incidence and outcomes of COVID-19 in IBD patients: a rapid review and meta-analysis. Inflamm Bowel Dis. 26:e132–e133. DOI: 10.1093/ibd/izaa170. PMID: 32619003. PMCID: PMC7337801.
Article
14. Singh S, Khan A, Chowdhry M, Bilal M, Kochhar GS, Clarke K. 2020; Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the United States: a multicenter research network study. Gastroenterology. 159:1575–1578.e4. DOI: 10.1053/j.gastro.2020.06.003. PMID: 32522507. PMCID: PMC7702184.
Article
15. Lukin DJ, Kumar A, Hajifathalian K, et al. 2020; Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. Gastroenterology. 159:1541–1544.e2. DOI: 10.1053/j.gastro.2020.05.066. PMID: 32479824. PMCID: PMC7256492.
Article
16. Brenner EJ, Ungaro RC, Gearry RB, et al. 2020; Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 159:481–491. e3. DOI: 10.1053/j.gastro.2020.05.032. PMID: 32425234. PMCID: PMC7233252.
Article
17. Rodríguez-Lago I, Ramírez de la Piscina P, Elorza A, Merino O, Ortiz de Zárate J, Cabriada JL. 2020; Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain). Gastroenterology. 159:781–783. DOI: 10.1053/j.gastro.2020.04.043. PMID: 32330477. PMCID: PMC7194905.
Article
18. Allocca M, Fiorino G, Zallot C, et al. 2020; Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clin Gastroenterol Hepatol. 18:2134–2135. DOI: 10.1016/j.cgh.2020.04.071. PMID: 32360811. PMCID: PMC7191273.
Article
19. Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. 2020; 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 52:276–283. DOI: 10.1111/apt.15804. PMID: 32359205. PMCID: PMC7267496.
Article
20. Gubatan J, Levitte S, Balabanis T, Patel A, Sharma A, Habtezion A. 2020; SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California. Gastroenterology. 159:1141–1144.e2. DOI: 10.1053/j.gastro.2020.05.009. PMID: 32387541. PMCID: PMC7204754.
Article
21. Guan WJ, Ni ZY, Hu Y, et al. 2020; Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720. DOI: 10.1056/NEJMoa2002032. PMID: 32109013. PMCID: PMC7092819.
Article
22. Zhou F, Yu T, Du R, et al. 2020; Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395:1054–1062. DOI: 10.1016/S0140-6736(20)30566-3. PMID: 32171076. PMCID: PMC7270627.
Article
23. Yang J, Zheng Y, Gou X, et al. 2020; Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 94:91–95. DOI: 10.1016/j.ijid.2020.03.017. PMID: 32173574. PMCID: PMC7194638.
Article
24. Vardavas CI, Nikitara K. 2020; COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 18:20. DOI: 10.18332/tid/119324. PMID: 32206052. PMCID: PMC7083240.
Article
25. Wenham C, Smith J, Morgan R. Gender and COVID-19 Working Group. 2020; COVID-19: the gendered impacts of the outbreak. Lancet. 395:846–848. DOI: 10.1016/S0140-6736(20)30526-2. PMID: 32151325. PMCID: PMC7124625.
Article
26. Patrì A, Pinchera B, Spirito L, et al. 2021; Gastrointestinal tract diseases as a risk factor for SARSCoV2 rectal shedding? An Italian report on 10 COVID-19 patients. Intest Res. 19:354–356. DOI: 10.5217/ir.2020.00084. PMID: 33147898. PMCID: PMC8322022.
Article
27. Barbosa da Luz B, de Oliveira NMT, França Dos Santos IW, et al. An overview of the gut side of the SARS-CoV-2 infection. Intest Res. 2020 Nov 6. [Epub ahead of print]. DOI: 10.5217/ir.2020.00087. PMID: 33142370.
Article
28. Hoffmann M, Kleine-Weber H, Schroeder S, et al. 2020; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:271–280.e8. DOI: 10.1016/j.cell.2020.02.052. PMID: 32142651. PMCID: PMC7102627.
Article
29. Park J, Jeong D, Chung YW, Kim DH, Cheon JH, Ryu JH. 2020; Quantitative proteomic analysis of the expression of SARS-CoV-2 receptors in the gut of patients with chronic enterocolitis. Yonsei Med J. 61:891–894. DOI: 10.3349/ymj.2020.61.10.891. PMID: 32975064. PMCID: PMC7515777.
Article
30. Burgueño JF, Reich A, Hazime H, et al. 2020; Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD. Inflamm Bowel Dis. 26:797–808. DOI: 10.1093/ibd/izaa085. PMID: 32333601. PMCID: PMC7188157.
Article
31. Rubin DT, Feuerstein JD, Wang AY, Cohen RD. 2020; AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology. 159:350–357. DOI: 10.1053/j.gastro.2020.04.012. PMID: 32283100. PMCID: PMC7151253.
Article
32. Kennedy NA, Jones GR, Lamb CA, et al. 2020; British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 69:984–990. DOI: 10.1136/gutjnl-2020-321244. PMID: 32303607. PMCID: PMC7211081.
Article
33. Aysha AA, Rentsch C, Prentice R, et al. 2020; Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. Intern Med J. 50:798–804. DOI: 10.1111/imj.14889. PMID: 32656985. PMCID: PMC7405147.
34. Ludvigsson JF, Axelrad J, Halfvarson J, et al. 2021; Inflammatory bowel disease and risk of severe COVID-19: a nationwide populationbased cohort study in Sweden. United European Gastroenterol J. 9:177–192. DOI: 10.1002/ueg2.12049. PMID: 33704918. PMCID: PMC8014882.
Article
35. Toruner M, Loftus EV Jr, Harmsen WS, et al. 2008; Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 134:929–936. DOI: 10.1053/j.gastro.2008.01.012. PMID: 18294633. PMCID: PMC6526151.
Article
36. Singh AK, Jena A, Kumar-M P, Jha DK, Sharma V. Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis. Intest Res. 2021 Jan 18. [Epub ahead of print]. DOI: 10.5217/ir.2020.00108. PMID: 33440918.
Article
37. Tian Y, Rong L, Nian W, He Y. 2020; Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 51:843–851. DOI: 10.1111/apt.15731. PMID: 32222988. PMCID: PMC7161803.
Article
38. Redd WD, Zhou JC, Hathorn KE, et al. 2020; Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: a multicenter cohort study. Gastroenterology. 159:765–767.e2. DOI: 10.1053/j.gastro.2020.04.045. PMID: 32333911. PMCID: PMC7195377.
Article
39. Wang D, Hu B, Hu C, et al. 2020; Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 323:1061–1069. DOI: 10.1001/jama.2020.1585. PMID: 32031570. PMCID: PMC7042881.
Article
40. Han C, Duan C, Zhang S, et al. 2020; Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol. 115:916–923. DOI: 10.14309/ajg.0000000000000664. PMID: 32301761. PMCID: PMC7172493.
Article
41. Cheung KS, Hung IFN, Chan PPY, et al. 2020; Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology. 159:81–95. DOI: 10.1053/j.gastro.2020.03.065. PMID: 32251668. PMCID: PMC7194936.
Article
42. Harmer D, Gilbert M, Borman R, Clark KL. 2002; Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 532:107–110. DOI: 10.1016/S0014-5793(02)03640-2. PMID: 12459472.
Article
43. Goyal P, Choi JJ, Pinheiro LC, et al. 2020; Clinical characteristics of COVID-19 in New York City. N Engl J Med. 382:2372–2374. DOI: 10.1056/NEJMc2010419. PMID: 32302078. PMCID: PMC7182018.
Article
44. Britton GJ, Chen-Liaw A, Cossarini F, et al. 2021; Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. Sci Rep. 11:13308. DOI: 10.1038/s41598-021-92740-9. PMID: 34172783. PMCID: PMC8233421.
Article
45. Rahier JF, Magro F, Abreu C, et al. 2014; Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 8:443–468. DOI: 10.1016/j.crohns.2013.12.013. PMID: 24613021.
Article
46. Magro F, Rahier JF, Abreu C, et al. 2020; Inflammatory bowel disease management during the COVID-19 outbreak: the Ten Dós and Don'ts from the ECCO-COVID taskforce. J Crohns Colitis. 14(14 Suppl 3):S798–S806. DOI: 10.1093/ecco-jcc/jjaa160. PMID: 32722754. PMCID: PMC7454472.
47. Hrusak O, Kalina T, Wolf J, et al. 2020; Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer. 132:11–16. DOI: 10.1016/j.ejca.2020.03.021. PMID: 32305831. PMCID: PMC7141482.
Article
48. Bussalino E, De Maria A, Russo R, Paoletti E. 2020; Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS-CoV-2 pneumonia: a case report. Am J Transplant. 20:1922–1924. DOI: 10.1111/ajt.15920. PMID: 32282991. PMCID: PMC7262360.
49. D'Antiga L. 2020; Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 26:832–834. DOI: 10.1002/lt.25756. PMID: 32196933. PMCID: PMC7300680.
50. Blanco JL, Ambrosioni J, Garcia F, et al. 2020; COVID-19 in patients with HIV: clinical case series. Lancet HIV. 7:e314–e316. DOI: 10.1016/S2352-3018(20)30111-9. PMID: 32304642. PMCID: PMC7159872.
Article
51. Ungaro RC, Brenner EJ, Gearry RB, et al. 2021; Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 70:725–732. DOI: 10.1136/gutjnl-2020-322539. PMID: 33082265. PMCID: PMC8136807.
Article
52. Agrawal M, Brenner EJ, Zhang X, et al. 2021; Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD registry. Inflamm Bowel Dis. 27:585–589. DOI: 10.1093/ibd/izaa303. PMID: 33325523. PMCID: PMC7799122.
Article
53. An P, Ji M, Ren H, et al. Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan, China. Lancet. 2020 Feb 27. [Preprints]. DOI: 10.2139/ssrn.3543590.
Article
54. Ni YN, Chen G, Sun J, Liang BM, Liang ZA. 2019; The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 23:99. DOI: 10.1186/s13054-019-2395-8. PMID: 30917856. PMCID: PMC6437920.
Article
55. Stockman LJ, Bellamy R, Garner P. 2006; SARS: systematic review of treatment effects. PLoS Med. 3:e343. DOI: 10.1371/journal.pmed.0030343. PMID: 16968120. PMCID: PMC1564166.
Article
56. Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. 2019; Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2:CD010406. DOI: 10.1002/14651858.CD010406.pub3. PMID: 30798570. PMCID: PMC6387789.
Article
57. Arabi YM, Mandourah Y, Al-Hameed F, et al. 2018; Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 197:757–767. DOI: 10.1164/rccm.201706-1172OC. PMID: 29161116.
Article
58. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020. [Internet]. 2020. World Health Organization;Geneva: cited 2021 Jul 28. Available from https://apps.who.int/iris/handle/10665/330893.
59. Lim HW, Schuster IP, Rajapakse R, Monzur F, Khan S, Sultan K. 2019; The impact of corticosteroid use on inpatients with inflammatory bowel disease and positive polymerase chain reaction for Clostridium difficile. Intest Res. 17:244–252. DOI: 10.5217/ir.2018.00101. PMID: 30739437. PMCID: PMC6505088.
Article
60. Cline JC, Davis SM. 1997; Risks of infection or reactivation of tuberculosis associated with chronic corticosteroid therapy. Ann Pharmacother. 31:775–776. PMID: 9184722.
61. Ling KL, Hilmi I, Raja Ali RA, et al. 2020; Asian Pacific Association of Gastroenterology (APAGE) inflammatory bowel disease (IBD) working party guidelines on IBD management during the COVID-19 pandemic. JGH Open. 4:320–323. DOI: 10.1002/jgh3.12362. PMID: 32514431. PMCID: PMC7273734.
Article
62. Kim KO, Jang BI. Management of inflammatory bowel disease in the COVID-19 era. Intest Res. 2021 Feb 3. [Epub ahead of print]. DOI: 10.5217/ir.2020.00156. PMID: 33525860.
Article
63. Zingone F, Savarino EV. 2020; Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. Lancet Gastroenterol Hepatol. 5:525. DOI: 10.1016/S2468-1253(20)30085-6. PMID: 32220656. PMCID: PMC7270848.
Article
64. D'Amico F, Danese S, Peyrin-Biroulet L. ECCO COVID taskforce. 2020; Inflammatory bowel disease management during the Coronavirus-19 outbreak: a survey from the European Crohn's and Colitis Organization. Gastroenterology. 159:14–19.e3. DOI: 10.1053/j.gastro.2020.04.059. PMID: 32360567. PMCID: PMC7191276.
65. Dotan I, Panaccione R, Kaplan GG, O'Morain C, Lindsay JO, Abreu MT. 2020; Best practice guidance for adult infusion centres during the COVID-19 pandemic: report from the COVID-19 International Organization for the Study of IBD [IOIBD] task force. J Crohns Colitis. 14(14 Suppl 3):S785–S790. DOI: 10.1093/ecco-jcc/jjaa147. PMID: 32959882. PMCID: PMC7543377.
Article
66. Van Assche G, Vermeire S, Ballet V, et al. 2012; Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 61:229–234. DOI: 10.1136/gutjnl-2011-300755. PMID: 21948942.
Article
67. Heida A, Dijkstra A, Muller Kobold A, et al. 2018; Efficacy of home telemonitoring versus conventional follow-up: a randomized controlled trial among teenagers with inflammatory bowel disease. J Crohns Colitis. 12:432–441. DOI: 10.1093/ecco-jcc/jjx169. PMID: 29228230.
Article
68. Lewin S, Lees C, Regueiro M, Hart A, Mahadevan U. 2020; International organization for the study of inflammatory bowel disease: global strategies for telemedicine and inflammatory bowel diseases. J Crohns Colitis. 14(14 Suppl 3):S780–S784. DOI: 10.1093/ecco-jcc/jjaa140. PMID: 33085971. PMCID: PMC7665391.
Article
69. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. 2015; Viral infections during pregnancy. Am J Reprod Immunol. 73:199–213. DOI: 10.1111/aji.12355. PMID: 25582523. PMCID: PMC4610031.
Article
70. Di Mascio D, Khalil A, Saccone G, et al. 2020; Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2:100107. DOI: 10.1016/j.ajogmf.2020.100107. PMID: 32292902. PMCID: PMC7104131.
71. Wong SF, Chow KM, Leung TN, et al. 2004; Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 191:292–297. DOI: 10.1016/j.ajog.2003.11.019. PMID: 15295381. PMCID: PMC7137614.
Article
72. Jeong SY, Sung SI, Sung JH, et al. 2017; MERS-CoV infection in a pregnant woman in Korea. J Korean Med Sci. 32:1717–1720. DOI: 10.3346/jkms.2017.32.10.1717. PMID: 28875620. PMCID: PMC5592190.
Article
73. Meijer WJ, van Noortwijk AG, Bruinse HW, Wensing AM. 2015; Influenza virus infection in pregnancy: a review. Acta Obstet Gynecol Scand. 94:797–819. DOI: 10.1111/aogs.12680. PMID: 26012384.
Article
74. Collin J, Byström E, Carnahan A, Ahrne M. 2020; Public Health Agency of Sweden's brief report: pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden. Acta Obstet Gynecol Scand. 99:819–822. DOI: 10.1111/aogs.13901. PMID: 32386441. PMCID: PMC7273089.
Article
75. Rosen MH, Axelrad J, Hudesman D, Rubin DT, Chang S. 2020; Management of acute severe ulcerative colitis in a pregnant woman with COVID-19 infection: a case report and review of the literature. Inflamm Bowel Dis. 26:971–973. DOI: 10.1093/ibd/izaa109. PMID: 32393973. PMCID: PMC7239163.
Article
76. Alsheef MA, Alabbad AM, Albassam RA, et al. 2020; Pregnancy and venous thromboembolism: risk factors, trends, management, and mortality. Biomed Res Int. 2020:4071892. DOI: 10.1155/2020/4071892. PMID: 32351991. PMCID: PMC7174915.
Article
77. De Lima-Karagiannis A, Juillerat P, Sebastian S, Pedersen N, Bar-Gil Shitrit A, van der Woude CJ. 2020; Management of pregnant inflammatory bowel disease patients during the COVID-19 pandemic. J Crohns Colitis. 14(14 Suppl 3):S807–S814. DOI: 10.1093/ecco-jcc/jjaa125. PMID: 33085970. PMCID: PMC7665400.
Article
78. Vassilopoulou E, Feketea G, Koumbi L, Mesiari C, Berghea EC, Konstantinou GN. 2021; Breastfeeding and COVID-19: from nutrition to immunity. Front Immunol. 12:661806. DOI: 10.3389/fimmu.2021.661806. PMID: 33897707. PMCID: PMC8058436.
Article
79. Zhu C, Liu W, Su H, et al. 2020; Breastfeeding risk from detectable severe acute respiratory syndrome coronavirus 2 in breastmilk. J Infect. 81:452–482. DOI: 10.1016/j.jinf.2020.06.001. PMID: 32505582. PMCID: PMC7270809.
Article
80. Breastfeeding and COVID-19: scientific brief, 23 June 2020. [Internet]. 2020. Geneva: World Health Organization;cited 2021 Jul 28. Available from https://apps.who.int/iris/handle/10665/332639.
81. Meyer A, Semenzato L, Zureik M, Weill A, Carbonnel F, Dray-Spira R. 2021; Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study. Aliment Pharmacol Ther. 54:160–166. DOI: 10.1111/apt.16410. PMID: 34110040.
Article
82. Siegel CA, Christensen B, Kornbluth A, et al. 2020; Guidance for restarting inflammatory bowel disease therapy in patients who withheld immunosuppressant medications during COVID-19. J Crohns Colitis. 14(14 Suppl 3):S769–S773. DOI: 10.1093/ecco-jcc/jjaa135. PMID: 33085972. PMCID: PMC7665410.
Article
83. Allez M, Fleshner P, Gearry R, Lakatos PL, Rubin DT. 2020; Care of the patient with IBD requiring hospitalisation during the COVID-19 pandemic. J Crohns Colitis. 14(14 Suppl 3):S774–S779. DOI: 10.1093/ecco-jcc/jjaa150. PMID: 32722757. PMCID: PMC7454473.
Article
84. Arons MM, Hatfield KM, Reddy SC, et al. 2020; Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 382:2081–2090. DOI: 10.1056/NEJMoa2008457. PMID: 32329971. PMCID: PMC7200056.
Article
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr